- ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
MD, Texas Tech Univ. Health Science Ctr
Residency, Internal Medicine
St. Lukes Roosevelt Hospital
Lenox Hill Hospital
Fellowship, Bone Marrow Trans.
Stanford University Hospital
Amir Steinberg, MD, FACP, is an assistant professor in the division of hematology-oncology at Mount Sinai Hospital. Dr. Steinberg's primary areas of focus are the hematologic malignancies and stem cell transplantation. He has a clinical interest in cancer survivorship as he is a lymphoma survivor himself. He is the principal investigator of a Hodgkin lymphoma study looking at the use of brentuximab in front-line therapy of newly diagnosed patients. He is also a co-investigator on several studies focused on transplant and the hematologic malignancies, particularly lymphoma.
He previously was a clinical assistant professor at UCLA on the staff of Cedars-Sinai Medical Center in Los Angeles. where his research focused on nonmyeloablative stem cell transplants for acute leukemia and novel therapies for relapsed central nervous system lymphomas.
A native Texan, Dr. Steinberg graduated magna cum laude from the University of Texas, Austin, with a bachelor's in history and a minor in biology. He earned his medical degree from Texas Tech University School of Medicine, and he completed his residency in internal medicine at St. Luke's and Roosevelt Hospitals (previously teaching hospitals of Columbia University) which are now both members of the Mt. Sinai Hospital System, Dr. Steinberg completed a fellowship in hematology-oncology at Lenox Hill Hospital. Subsequently, Dr. Steinberg completed a bone marrow transplant fellowship at Stanford University Hospital and Clinics in Palo Alto, California. Dr. Steinberg is board-certified in Medical Oncology, Hematology, and Internal Medicine.
Fellow of the American College of Physicians (FACP)
American College of Physicians (ACP)
Award of Excellence,
Southern California Cancer Pain Initiative,
New topicDr. Steinberg is the principal investigator of a Hodgkin lymphoma study looking at the use of brentuximab in front-line therapy of newly diagnosed patients. He is also a co-investigator on several studies focused on transplant and the hematologic malignancies, particularly lymphoma.
Masood A, Steinberg A, Moshier E, Malone A, Scigliano E, Nieto J, Osman K, Grosskreutz C, Isola L, Brody J. Retrospective analysis of prognosticators in patients with relapsed Hodgkin's Lymphoma treated with autologous transplant: results of a single center. Medical oncology (Northwood, London, England) 2013 Mar; 30(1).
Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, Chow R, Duncan C, Eldjerou LK, Gupta V, Hale GA, Halter J, Hayes-Lattin BM, Hsu JW, Jacobsohn DA, Kamble RT, Kasow KA, Lazarus HM, Mehta P, Myers KC, Parsons SK, Passweg JR, Pidala J, Reddy V, Sales-Bonfim CM, Savani BN, Seber A, Sorror ML, Steinberg A, Wood WA, Wall DA, Winiarski JH, Yu LC, Majhail NS. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012 Dec; 18(12).
Pham A, Steinberg A, Kwok B, Lopez A, Lim S, Lill M. Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder. Hematology reports 2011 Aug; 3(2).
Steinberg A, Kansal R, Wong M, Lopez A, Lim S, Lopategui J, Lill M. Good clinical response in a rare aggressive hematopoietic neoplasm: plasmacytoid dendritic cell leukemia with no cutaneous lesions responding to 4 donor lymphocyte infusions following transplant. Case reports in transplantation 2011; 2011.
Kim D, Kwok B, Steinberg A. Simultaneous acute myeloid leukemia and multiple myeloma successfully treated with allogeneic stem cell transplantation. Southern medical journal 2010 Dec; 103(12).
Pham A, Bahadini B, Alsabeh R, Steinberg A. First reported case of aplastic anemia occurring in a patient after acute promyelocytic leukemia in remission. Clinical advances in hematology & oncology : H&O 2009 Oct; 7(10).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Steinberg during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Alexion Pharmaceuticals, Inc.; Spectrum Pharmaceuticals, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 3rd Floor Room 3-29
1425 Madison Avenue
New York, NY 10029
1470 Madison Avenue
New York, NY 10029